Comment on

• Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.

  Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, Reiffers J, Praloran V, Mahon FX. Colombat M, et al. Haematologica. 2006 Feb;91(2):162-8. Haematologica. 2006. PMID: 16461299 Clinical Trial.
• The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.

  Wang L, Knight K, Lucas C, Clark RE. Wang L, et al. Haematologica. 2006 Feb;91(2):235-9. Haematologica. 2006. PMID: 16461309